The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.
NEW YORK – 858 Therapeutics on Thursday said it raised $50 million in a Series B financing round to advance its pipeline of small molecule therapeutics, including the poly (ADP) ribose glycohydrolase ...
The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.